[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Abdel-Misih SR, Schmidt CR, Bloomston PM: Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol; 2009;7:72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases.
  • BACKGROUND: The management of stage IV colorectal cancer with liver metastases has historically involved a multidisciplinary approach.
  • In the last several decades, there have been great strides made in the therapeutic options available to treat these patients with advancements in medical, surgical, locoregional and adjunctive therapies available to patients with colorectal liver metastases(CLM).
  • REVIEW: A review of historical and up to date literature was undertaken utilizing Medline/PubMed to examine relevant topics of interest in patients with CLM including criterion for resectability, technical/surgical considerations, chemotherapy, adjunctive and locoregional therapies.
  • CONCLUSION: Improvements in modern day chemotherapy as allowed clinicians to pursue a more aggressive surgical approach in the management of stage IV colorectal cancer with CLM.
  • Additionally, locoregional and adjunctive therapies has expanded the armamentarium of treatment options available.
  • As a result, the management of patients with CLM requires a comprehensive, multidisciplinary approach utilizing various modalities and a more aggressive approach may now be pursued in patients with stage IV colorectal cancer with CLM to achieve optimal outcomes.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Patient Care Team
  • [MeSH-minor] Humans. Neoplasm Staging. Patient Care Planning. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):559-65; discussion 565-7 [17893492.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3481-91 [17805933.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):710-5 [18039424.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):144-57 [17906898.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Am J Surg. 2008 Apr;195(4):508-20 [18361927.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):683-8 [18471041.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3672-80 [18669451.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2757-64 [18618182.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2765-72 [18636296.001]
  • [Cites] World J Surg Oncol. 2008;6:93 [18764938.001]
  • [Cites] Surg Oncol. 2008 Dec;17(4):295-9 [18472417.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):626-37 [18936576.001]
  • [Cites] Dig Surg. 2008;25(6):421-9 [19212114.001]
  • [Cites] Dig Surg. 2008;25(6):430-5 [19212115.001]
  • [Cites] Dig Surg. 2008;25(6):445-60 [19212117.001]
  • [Cites] Dig Surg. 2008;25(6):461-6 [19212118.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):985-92 [19153115.001]
  • [Cites] J Am Coll Surg. 2009 May;208(5):842-50; discussion 850-2 [19476847.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):879-86 [19474695.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):559-68 [19482548.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2138-46 [19495884.001]
  • [Cites] Ann Surg Oncol. 2009 Sep;16(9):2411-21 [19554376.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Surgery. 2000 May;127(5):512-9 [10819059.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] J Gastrointest Surg. 2001 May-Jun;5(3):294-302 [11360053.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):255-63 [11992812.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):221-9 [12620560.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):338-47 [12734080.001]
  • [Cites] Br J Surg. 2003 May;90(5):567-74 [12734864.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):243-55 [12735142.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1240-3 [14515293.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):114-21 [14714186.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):759-64 [15296990.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):727-31 [3756436.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):1-4 [3366020.001]
  • [Cites] Surgery. 1990 May;107(5):521-7 [2333592.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Hepatology. 1995 May;21(5):1317-21 [7737637.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] World J Surg. 1998 Apr;22(4):399-404; discussion 404-5 [9523523.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):40-6 [9609107.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1058-60 [9717995.001]
  • [Cites] J Am Coll Surg. 1998 Dec;187(6):620-5 [9849736.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):425-9 [15677624.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jun;16(6):779-90 [15947041.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):913-9 [15966231.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):900-9 [16184442.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Cancer Control. 2006 Jan;13(1):32-41 [16508624.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):651-8 [16538411.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Arch Surg. 2006 May;141(5):460-6; discussion 466-7 [16702517.001]
  • [Cites] Am Surg. 2006 May;72(5):391-2 [16719190.001]
  • [Cites] Arch Surg. 2006 Jun;141(6):581-7; discussion 587-8 [16785359.001]
  • [Cites] Surg Clin North Am. 2006 Aug;86(4):1005-22 [16905421.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):696-703 [16916386.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1261-8 [16947009.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4983-90 [17075116.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):67-71 [17174059.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):274-86 [17315288.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1151-60 [17195913.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1099-106 [17369573.001]
  • [Cites] J Vasc Interv Radiol. 2007 Apr;18(4):553-61; quiz 562 [17446547.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jul;16(3):525-36, viii [17606192.001]
  • [Cites] Arch Surg. 2007 Jul;142(7):675-82 [17638807.001]
  • [Cites] Zentralbl Chir. 2007 Aug;132(4):293-9 [17724630.001]
  • (PMID = 19788748.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 97
  • [Other-IDs] NLM/ PMC2763868
  •  go-up   go-down


2. Chala E, Manes C, Iliades H, Skaragkas G, Mouratidou D, Kapantais E: Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones (Athens); 2006 Apr-Jun;5(2):137-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy.
  • OBJECTIVE: To evaluate insulin values, insulin resistance, growth factors and cytokine levels in women suffering from breast cancer and the effect of chemotherapy on these parameters.
  • DESIGN: In a prospective study, glucose and insulin values were determined in ten previously undiagnosed diabetic postmenopausal women with stage IV breast cancer (hepatic metastases excluded) during an oral glucose tolerance test (OGTT) carried out after a glucose load of 75 g.
  • At baseline, leptin, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Insulin-Growth Factor-1 (IGF-1), Tumor-Necrosis-Factor-alpha (TNF-alpha), Vascular Endothelial Growth Factor (VEGF) and Platelet Derived Growth Factor (PDGF) levels were also determined using appropriate methodolody.
  • All women were evaluated prior to and after chemotherapy applied for 6 months. RESULTS:.
  • 1) Insulin levels at 120 minutes of the OGTT were higher before compared to post-chemotherapy (Mean+/-SD: 170.39+/-78.07 vs 111.75+/-76.19, p=0.037).
  • 2) Body mass index (BMI) was an important predictor of post-glucose load insulin levels both before (coefficient=1.051, p=0.004) and after chemotherapy (coefficient=0.711, p=0.003).
  • 3) Before chemotherapy BMI values were positively related to PDGF levels (rs=0.685, p=0.029), while after chemotherapy this relationship became non-significant (rs=0.188, p=0.603).
  • Before chemotherapy there was a negative relationship between VEGF and waist circumference (coefficient= -0.542, p=0.023).
  • CONCLUSIONS: Post-glucose load insulin values significantly decrease after chemotherapy.
  • There is a positive relationship between BMI and post-glucose load insulin before and after chemotherapy.
  • The contribution of the reduction in insulin, a known growth factor, to the outcome of chemotherapy in these patients remains speculative at present.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Cytokines / blood. Growth Substances / blood. Insulin Resistance. Overweight / drug effects
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Blood Glucose / analysis. Body Mass Index. Diabetes Mellitus / diagnosis. Female. Fluorouracil / therapeutic use. Glucose Tolerance Test. Humans. Insulin / blood. Liver Neoplasms / drug therapy. Middle Aged. Neoplasm Metastasis / drug therapy. Postmenopause / drug effects. Waist-Hip Ratio

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807226.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Blood Glucose; 0 / Cytokines; 0 / Growth Substances; 0 / Insulin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Tisman G: Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report. Tumori; 2009 Nov-Dec;95(6):804-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report.
  • Metastatic breast cancer to the liver is considered incurable.
  • Though many patients with liver metastases may enjoy response to chemo-, immuno- and hormonal therapy, those so inflicted rarely remain disease-free from the time of diagnosis for longer than 6-11 months.
  • New laboratory and clinical research identified that cross-talk between activation of the epidermal growth factor family of tyrosine kinase transduction pathways (EGF/HER2) and estrogen receptor (ER) activation plays a role in resistance to hormonal therapy.
  • A 59-year-old woman with a 4.5-cm invasive ductal, ER-positive/PR-negative, grade III adenocarcinoma of the breast was treated with mastectomy.
  • Staging revealed biopsy-proven liver metastases.
  • It is proposed that a possible mechanism for prolonged remission of stage IV breast cancer in this patient may be related to suppression of EGF/HER2 by trastuzumab, thus inhibiting cross-talk-associated tamoxifen/estrogen withdrawal resistance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Receptor Cross-Talk / drug effects. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Androstadienes / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Female. Humans. Mastectomy, Modified Radical. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Tamoxifen / administration & dosage. Tomography, X-Ray Computed. Trastuzumab. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. EXEMESTANE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210247.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen; 5V9KLZ54CY / Vinblastine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; NY22HMQ4BX / exemestane; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


Advertisement
4. Martínez C J, Jarufe C N, González D R, Alvarez Z M: [Current therapeutic options for liver metastasis]. Rev Med Chil; 2008 Mar;136(3):376-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current therapeutic options for liver metastasis].
  • [Transliterated title] Alternativas terapéuticas actuales de las metástasis hepáticas.
  • The liver is a common site of hematogenous metastasis, especially from gastrointestinal malignancies.
  • Liver metastasis are generally classified as stage IV disease.
  • Previously treatment in such patients was met with great skeptiscism.
  • However, advances in surgical and medical therapies during the last two decades have provided effective therapeutic options for selected patients.
  • Since major hepatic resections are now performed with acceptable morbidity and a mortality rate <3%, colorectal cancer metastasis to the liver are associated with 5-year survival rates of 30% or more.
  • Meanwhile, a variety of new therapies have been developed, including hepatic artery infusion of chemotherapy; alcoholic, crio and radiofrequency ablation and novel strategies of systemic chemotherapy with the development of molecular targeted new products.
  • These new therapeutic armamentarium have been used mostly in liver metastasis from colorectal cancer patients.
  • However, liver metastasis of neuroendocrine tumors and selected cases of non colorectal cancer liver metastasis are benefited from the same strategies.
  • This report summarizes the different therapeutic tools, their advantages and results mainly on colorectal cancer liver metastasis.
  • [MeSH-major] Carcinoma / therapy. Colorectal Neoplasms / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Catheter Ablation. Combined Modality Therapy. Cryosurgery. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Hepatectomy. Humans. Neoplasm Staging. Prognosis. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575666.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 40
  •  go-up   go-down


5. Fournier C, Tisman G, Kleinman R, Park Y, Macdonald WD: Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report. J Med Case Rep; 2010;4:112

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report.
  • INTRODUCTION: We report a case of stage IV breast cancer terminating in an unusual picture of radiologically occult micronodular pseudo-cirrhosis.
  • Contrast-enhanced computed tomography showed no evidence of metastatic breast cancer within the liver.
  • Unlike the few previously reported cases of intrasinusoidal spread of breast cancer, our patient was palliated with a transjugular intrahepatic portosystemic shunt along with salvage chemohormonal therapy.
  • In addition, our patient demonstrated proof of the principle of the dependence of capecitabine (Xeloda) efficacy on dose scheduling as predicted by laboratory studies based on Gompertzian tumor growth and the Norton-Simon hypothesis.
  • CASE PRESENTATION: We report the case of a 52-year-old Caucasian woman who developed radiological signs of portal hypertension without radiological evidence of hepatic metastasis five years after being diagnosed with metastatic breast cancer.
  • She was receiving chemotherapy for stage IV breast cancer initially thought to be metastatic only to the bones.
  • During salvage therapy with high-dose estradiol (Estradiol valerate), vinorelbine (Navelbine) and bevacizumab (Avastin), she suddenly developed signs of portal hypertension confirmed on computed tomography and by portal and systemic venous pressure measurements.
  • Drug toxicity due to bevacizumab (Avastin) was initially and incorrectly entertained as a cause.
  • The patient underwent palliative transjugular intrahepatic portosystemic shunt and transhepatic venous liver biopsy, which revealed the presence of rapidly progressive and uncontrolled metastatic breast cancer.
  • The new discovery of radiologically occult intrasinusodal hepatic metastases with secondary micronodular cirrhosis was found to be the cause of her sudden onset portal hypertension.
  • The patient's resistance to capecitabine (Xeloda) was reversed by changing the schedule of medication to biweekly 7/7 (7 days ingesting drug alternating with 7 days off drug) from the 14/7 (14 days ingesting drug alternating with a 7 day rest period) day schedule approved by the US Food and Drug Administration.
  • CONCLUSION: This case report demonstrates an unusual presentation of radiographically occult hepatic metastasis from breast cancer palliated with transjugular intrahepatic portosystemic shunt.
  • All patients with advanced breast cancer developing unexpected portal hypertension should be considered candidates for liver biopsy despite normal computed tomography of the liver imaging results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1797-802 [18398145.001]
  • [Cites] Arch Pathol Lab Med. 2004 Dec;128(12):1418-23 [15578887.001]
  • [Cites] Eur J Radiol. 2007 Jan;61(1):57-69 [17145154.001]
  • (PMID = 20409335.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2865501
  •  go-up   go-down


6. Aoyagi K, Koufuji K, Yano S, Murakami N, Miyagi M, Takeda J, Shirouzu K: Long-term survival after gastric cancer with liver metastasis: a report of two cases. Kurume Med J; 2001;48(4):335-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after gastric cancer with liver metastasis: a report of two cases.
  • We have experienced two cases of long-term survival after surgery for gastric cancer case with liver metastasis.
  • One case was of a 66-year-old male patient diagnosed as having type 1 advanced gastric cancer located in the posterior wall of the lower body with liver metastasis.
  • The stage of this case was P0H1N1T2M0 stage IV.
  • This patient underwent distal gastrectomy with D2 lymph node resection, partial hepatectomy of the S3 region including the metastatic liver tumor and coagulation of metastatic liver tumors in the S6 and S7 regions.
  • This patient was treated by intra-hepatic arterial infusion of 5-FU, CDDP and peroral administration of UFT after surgery.
  • The other case was of a 55-year-old male patient diagnosed as having type 2 advanced gastric cancer located in the lesser curvature of the cardia with liver metastasis.
  • The stage of this case was P0H1N1T3 M0 stage IV.
  • This patient underwent total gastrectomy with D2 lymph node dissection, wedge resection of the S8 region including the metastatic liver tumor and coagulation of a metastatic liver tumor in the S4 region.
  • This patient was treated by obstruction of the hepatic artery using coils, peroral administration of UFT, lentinan, MMC, and continuous low-dosage 5-FU and CDDP after surgery.
  • These results suggest that for long-term survival in cases of gastric cancer with liver metastasis, hepatectomy or coagulation of the metastatic tumor with postoperative chemotherapy are indicated in cases that have no non-curative factors and only a few metastatic tumors.
  • [MeSH-major] Liver Neoplasms / secondary. Stomach Neoplasms / mortality
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Middle Aged. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11830935.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, Neugut AI: Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer; 2007 Dec 17;97(12):1606-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival after hepatic resection among patients with colorectal liver metastasis.
  • Studies suggest improved survival following resection of colorectal cancer liver metastases (CLMs).
  • We investigated predictors of survival among patients with CLM who underwent hepatic resection using the SEER-Medicare database to identify patients >/=65 years diagnosed with CLM, 1991-2003, who underwent hepatectomy.
  • Of 923 patients with CLM who underwent hepatectomy, 514 were stages I-III and developed CLM>6 months after diagnosis (metachronous), and 409 were stage IV with CLM at diagnosis (synchronous).
  • From the date of hepatectomy, 5 year survival was 22%; younger age, being married, female gender, surgery in an NCI-designated cancer centre, fewer comorbidities, fewer positive lymph nodes, and lower grade were associated with improved survival.
  • Both 5-fluorouracil (5FU)-based chemotherapy and hepatic arterial infusion (HAI) of floxuridine-based chemotherapy following hepatectomy improved survival (HR=0.62, 95% CI: 0.50-0.78; HR=0.51, 95% CI: 0.28-0.97, respectively) in the synchronous, but not metachronous, group.
  • The HR for overall mortality was higher in hospitals with a high vs low procedure volume (0.75, 95% CI: 0.58-0.94).
  • High hospital procedure volume and use of 5FU-based or HAI-based chemotherapy after resection were associated with improved prognosis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):805-11 [9684138.001]
  • [Cites] Hepatogastroenterology. 1995 Apr;42(2):155-61 [7672764.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):756-62 [9860474.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] J Pathol. 2005 Jan;205(2):275-92 [15641020.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Abdom Imaging. 2005 Jul-Aug;30(4):419-26 [15759208.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):86-94 [16368496.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):557-63 [16580811.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(12):1845-7 [17212124.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):718-26 [17238180.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1549-56 [10738212.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Surgery. 2001 Apr;129(4):408-13 [11283530.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):501-15 [11287444.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):196-202 [12168966.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-19-25 [12187164.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-26-35 [12187165.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-43-8 [12187167.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Arch Surg. 2003 Feb;138(2):185-91 [12578418.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):871-83; discussion 883-4 [14631224.001]
  • [Cites] Surg Gynecol Obstet. 1970 Oct;131(4):697-700 [5458530.001]
  • [Cites] Arch Surg. 1976 Apr;111(4):330-4 [1259571.001]
  • [Cites] Am J Surg. 1978 Mar;135(3):389-94 [626320.001]
  • [Cites] J Chronic Dis. 1986;39(6):439-52 [3086355.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Curr Probl Surg. 1995 May;32(5):333-421 [7538062.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • (PMID = 18071347.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA095597; United States / NCI NIH HHS / CA / R25 CA094061; United States / NLM NIH HHS / LM / T15 LM007079; United States / NCI NIH HHS / CA / CA94061
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2360280
  •  go-up   go-down


8. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • For patients with extensive liver metastases, FOLFOX and FOLFIRI have improved resection rates and survival.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • METHODS: Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008.
  • Patients received neoadjuvant chemoradiation and adjuvant FOLFOX or FOLFIRI therapy.
  • The outcomes for patients who underwent synchronous resection, staged resection, resection of rectal tumor only, and no resection with chemotherapy only were compared.
  • RESULTS: Seventy-four patients were identified: 30 synchronous resections, 13 staged resections, 22 primary resection only, and 9 no resection.
  • Sixty-five percent of patients underwent liver resection with 26% rendered eligible for resection after adjuvant therapy.
  • Those who underwent primary resection only had shorter median survival than those who underwent either staged or synchronous liver resection (31 vs. 47 vs. 46 months, respectively; P = 0.17).
  • Volume of liver disease predicted resectability (P = 0.001).
  • Without liver resection, 2-year survival was approximately 60%.
  • Palliative surgery was required in six of nine patients who did not undergo resection of their primary tumor.
  • CONCLUSIONS: Current chemotherapeutic regimens lead to improved survival in patients with unresectable liver metastases.
  • Upfront chemotherapy in the asymptomatic patient compared with resection of the primary tumor does not appear to significantly affect survival.
  • However, given that 60% of patients were alive after 2 years, resection of the primary lesion for palliative reasons and local control must be considered.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):592-8 [18936572.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2283-92 [12436433.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5910-7 [19018087.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):35-41 [18987915.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Oncologist. 1999;4(3):197-208 [10394588.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1829-35 [18662955.001]
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Gervaz P, Rubbia-Brandt L, Andres A, Majno P, Roth A, Morel P, Mentha G: Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol; 2010 Oct;17(10):2714-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
  • BACKGROUND: We report the histopathological results of a novel "inversed" strategy designed to manage patients with colorectal cancer (CRC) who have synchronous liver metastases by using chemotherapy first, liver surgery second, and resection of the primary tumor as a final step.
  • This study was designed to compare the response to chemotherapy in liver metastases, primary tumors, and locoregional lymph nodes.
  • METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months.
  • Histological response to chemotherapy was assessed by using a tumor regression grading (TRG) score based on presence of residual tumor cells and extent of fibrosis.
  • Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients).
  • TRG scores correlated across disease sites (Spearman correlation coefficients for TRG in the primary tumor and lymph nodes was 0.59 [P = 0.005]; for the primary tumor and metastases 0.44 [P = 0.021]; and for lymph nodes and metastases 0.58 [P = 0.006]).
  • Complete absence or poor tumor response (TRG4/5) was significantly more frequent in primary tumors (35.7%) and locoregional lymph nodes (38%) than in liver metastases (6.9%; McNemar test, P = 0.02).
  • CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymph Nodes / drug effects. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405223.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Patwardhan M, Fisher DA, Mantyh CR, McCrory DC, Morse MA, Prosnitz RG, Cline K, Samsa GP: Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature). J Eval Clin Pract; 2007 Dec;13(6):831-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature).
  • RATIONALE, AIMS AND OBJECTIVES: The burden of illness from colorectal cancer (CRC) can be reduced by improving the quality of care.
  • We identified process measures currently available to assess the quality of diagnosis and management of CRC.
  • We identified 3771 abstracts and reviewed 74 articles that included quality measures for diagnosis or management of CRC.
  • Most measures are important, but need to be developed and field-tested.
  • The best available measures relate to pathology and chemotherapy.
  • No measures are available for assessing quality of management of stage IV rectal cancer and hepatic metastasis; chemotherapy for stage II colon cancer; and procedure notes.
  • [MeSH-major] Colonic Neoplasms / therapy. Quality Assurance, Health Care / standards. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070253.001).
  • [ISSN] 1356-1294
  • [Journal-full-title] Journal of evaluation in clinical practice
  • [ISO-abbreviation] J Eval Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 117
  •  go-up   go-down


11. Lam MS, Kaufman DA, Russin MP: Capecitabine-associated cerebellar ataxia. Am J Health Syst Pharm; 2008 Nov 1;65(21):2032-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: A 65-year-old white woman with stage IV colorectal cancer with liver metastasis was started on a chemotherapy regimen of capecitabine, oxaliplatin, and bevacizumab, given every three weeks.
  • She tolerated the first two treatment cycles fairly well without major toxicities.
  • On day 12 of the fourth treatment cycle, she reported ongoing lightheadedness and progressive gait disturbance with worsening ataxia over the past 3 days.
  • Her capecitabine dosage was further reduced to 2000 mg daily, and the time between treatment intervals was increased to four weeks.
  • The patient continued to experience intermittent, but less severe, ataxia during the fifth treatment cycle.
  • On the day before the seventh cycle was to begin, she had ataxic gait and could not walk without assistance.
  • The chemotherapy was postponed for a total of six weeks until the ataxia completely resolved.
  • Her chemotherapy was ultimately discontinued due to disease progression.
  • Her neurologic symptoms did not recur.
  • CONCLUSION: A patient receiving capecitabine-containing chemotherapy developed persistent but reversible cerebellar ataxia.
  • [MeSH-major] Cerebellar Ataxia / chemically induced. Cerebellar Ataxia / diagnosis. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

  • Genetic Alliance. consumer health - Cerebellar Ataxia.
  • Genetic Alliance. consumer health - Ataxia.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945862.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Kanemitsu K, Baba H: Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol; 2007 Sep-Oct;30(5):912-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
  • PURPOSE: The purpose of this study was to compare intrahepatic and pancreatic perfusion on fusion images using a combined single-photon emission computed tomography (SPECT)/CT system and to evaluate the efficacy of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in the treatment of advanced pancreatic carcinoma.
  • MATERIALS AND METHODS: CTAI was performed in 33 patients (22 men, 11 women; age range, 35-77 years; mean age, 60 years) with stage IV pancreatic cancer with liver metastasis.
  • Pancreatic perfusion on fusion images was classified as perfusion presence or as perfusion absent in the pancreatic cancer.
  • Using WHO criteria we recorded the tumor response after 3 months on multislice helical CT scans.
  • Treatment effects were evaluated based on the pancreatic cancer, liver metastasis, and factors such as intrahepatic and pancreatic perfusion on fusion images.
  • Patients with hot spot in the pancreatic tumor and homogeneous distribution in the liver manifested better treatment results (p < 0.05 and p < 0.01, respectively).
  • Patients with hot spot both in the pancreatic cancer and in the liver survived longer than those with cold spot in the pancreatic cancer and heterogeneous distribution in the liver (median +/- SD, 16.0 +/- 3.7 vs. 8.0 +/- 1.4 months; p < 0.05).
  • CONCLUSIONS: We conclude that in patients with advanced pancreatic cancer, CTAI with systemic chemotherapy appeared to be effective and may prolong their survival.
  • The development of a reservoir port system allowing for the homogeneous distribution of anticancer drugs is necessary to improve the prognosis of patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Pancreatic Ductal / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy. Tomography, Emission-Computed, Single-Photon / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Catheters, Indwelling. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Equipment Design. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Injections, Intravenous. Kaplan-Meier Estimate. Liver Circulation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Regional Blood Flow. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710478.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Matsutani T, Suzuki S, Mizutani T, Miyamoto M, Maruyama H, Yokoyama T, Yanagi K, Matsushita A, Kashiwabara M, Matsuda A, Nishi Y, Arai H, Sasajima K, Tajiri T: [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1193-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
  • A 75-year-old man with advanced gastric cancer underwent distal gastrectomy with lymph node dissection(D1)and Roux-en Y reconstruction.
  • Pathological staging was Stage IV (T3N3P1CY1M1), and curability was Cur C.
  • He started adjuvant chemotherapy with oral administration of S-1(100 mg/body weight), but experienced grade 3 anorexia for one month.
  • Abdominal computed tomography(CT)2 months postoperatively showed multiple liver metastases and ascites.
  • We then conducted tailored S-1/CPT-11 as second-line chemotherapy(S-1 80 mg/body weight on days 1-5 and 8-12, CPT-11 60 mg/body weight on days 1 and 8).
  • After 5 courses of this therapy, CT showed that the liver metastases and ascites had disappeared, leading to a complete response(CR).
  • He continues to undergo oral administration of S-1(80 mg/body weight)as maintenance therapy, and maintained CR for 12 months since undergoing chemotherapy.
  • Adverse events in tailored S-1/CPT-11 combination therapy are mild and tolerable, making this regimen a potential therapeutic strategy for patients with advanced or recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Gastroscopy. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633261.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Loupakis F, Falcone A: Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC? Nat Rev Clin Oncol; 2010 Apr;7(4):190-1
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
  • Patients who undergo hepatic surgery for initially resectable liver metastases from colorectal cancer have a 70% risk of relapse. a recent phase III randomized trial has failed to demonstrate an improvement in disease-free survival with the addition of irinotecan to 5-fluorouracil and folinic acid as adjuvant treatment for patients with radically resected colorectal cancer with liver metastases.
  • [MeSH-major] Camptothecin / analogs & derivatives. Colorectal Neoplasms / drug therapy. Leucovorin / therapeutic use. Liver Neoplasms / secondary
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Confidence Intervals. Fluorouracil / therapeutic use. Humans. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Survival Analysis. Vitamin B Complex / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354542.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 12001-76-2 / Vitamin B Complex; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


15. Kawarada Y, Yamagiwa K: [Up to date of multidisciplinary treatments centering around hepatectomy for advanced liver cancer in stage IV-A]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1489-95
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Up to date of multidisciplinary treatments centering around hepatectomy for advanced liver cancer in stage IV-A].
  • Patients with advanced Stage IV-A primary liver cancer, hepatocellular carcinoma (HCC) can be divided into subgroups: those with involvement of a major branch of the portal (Vp3) or hepatic (Vv2, Vv3) veins and those having multiple tumors in both lobes without Vp3 or Vv2, Vv3.
  • The prognosis of Stage IV-A patients with Vv2 or Vv3 may be improved by extended hepatectomy with resection and reconstruction of hepatic veins or IVC.
  • In those with Vp3, multidisciplinary treatments consisting of extended hepatectomy and adjuvant chemotherapy, i.e. intra-arterial injection or TACE, are thought to be feasible at the present, but the outcomes are still poor.
  • On the other hand, there are some Stage IV-A patients with multi-centrical tumors who have multiple tumors in both lobes without major vascular invasion, and their prognoses are improved by partial resection of each tumor.
  • However, when there are multiple tumors caused by intrahepatic metastases, multidisciplinary treatments consisting of reduction surgery, microwave ablation, ethanol injection, and intra-arterial chemotherapy might be useful at present.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015991.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 8
  •  go-up   go-down


16. Hsu C, Lin Z, Lee K, Yeh K, Hsiao C, Shen Y, Chang D, Wang S, Hsu C, Cheng A: A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report. J Clin Oncol; 2009 May 20;27(15_suppl):e15533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report.
  • Tegafur/uracil (UFT) is an oral prodrug of 5-fluorouracil with activity against various gastrointestinal cancers.
  • Metronomic chemotherapy has been shown to have anti-angiogenic and anti-cancer effect in preclinical and clinical models.
  • This study evaluated the efficacy and safety of the combination of T and metronomic UFT as first-line therapy for advanced HCC.
  • METHODS: Patients (Pts) with advanced HCC not treatable by surgery or other loco-regional therapies received T 100mg bid and UFT 125mg/m<sup>2</sup> (based on tegafur) bid continuously.
  • Treatment was continued in the absence of disease progression or unacceptable toxicity.
  • Primary endpoint was response rate (RR) by RECIST; secondary endpoints were disease control rate (CR+PR+SD), progression-free survival (PFS), overall survival (OS), and safety.
  • Baseline characteristics were HBsAg(+)/anti-HCV(+)/both(+) /both(-) 31/6/1/7; AJCC stage II/III/IV 2/18/23; BCLC stage B/C 1/42; CLIP score ≤3/4 27/16; portal vein thrombosis 65%; extrahepatic metastasis 58%; prior local treatment 72%.
  • There were 4 PR (9.3%) and 10 SD (23.3%), with a disease control rate of 32.6%.
  • Grade 3 leucopenia developed in 1 (2.3%) pt.
  • The most common treatment-related grade 3 non-hematologic toxicities were somnolence (n=4, 9.3%), GI bleeding (n=3, 7.0%), and elevated transaminase (n=2, 4.7%).
  • CONCLUSIONS: The combination of T with metronomic UFT is a well-tolerated regimen with moderate activity for advanced HCC, and worth further exploration in pts with CLIP score ≤3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The primary outcome measures of the study were (1) to assess the radiological tumor response;.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV.
  • According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • METHODS: Using a prospective database, we analyzed potential risk factors in 233 patients, who were electively operated for non-curable stage IV CRC between 1996 and 2002.
  • Patients with recurrent tumors, resectable metastases, emergency operations, and non-resective surgery were excluded.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • Prognostic factors for limited postoperative survival were hepatic tumor load >50%, pT4 tumors, lymphatic spread, R1-2 resection, and lack of chemotherapy.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • For such patients, surgery might be contraindicated unless the tumor is immediately life-threatening.
  • [MeSH-major] Colonic Neoplasms / surgery. Elective Surgical Procedures / adverse effects. Palliative Care. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Comorbidity. Female. Humans. Liver Neoplasms. Male. Middle Aged. Morbidity. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):3-7 [12210018.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1099-106 [18181002.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):262-5 [15019919.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):699-709 [19221767.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):407-11; discussion 412 [11182388.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):156-60 [9075749.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):551-6 [12297977.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1116-20 [8869321.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):580-5 [10805846.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1425-9 [9407979.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1818-25 [18095024.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] Dis Colon Rectum. 1981 Nov-Dec;24(8):606-9 [6172244.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Surgery. 2005 Jan;137(1):42-7 [15614280.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):864-8 [6171042.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Rathore R, Safran H, Soares G, Dubel G, McNulty B, Ahn S, Iannitti D, Kennedy T: Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol; 2010 Feb;33(1):43-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study.
  • PURPOSE: We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular carcinoma (HCC).
  • The therapy was continued until disease progression or excessive toxicity not amenable to appropriate modifications.
  • Stage distribution was as follows: stage II, 3 patients; stage III, 12 patients; and stage IV, 8 patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Hepatic Artery. Liver Neoplasms / drug therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Infusions, Intra-Arterial. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687731.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


20. Kamiyama T, Nakagawa T, Nakanishi K, Kurauchi N, Kamachi H, Matsushita M, Todo S: [Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1618-20
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma].
  • Postoperative adjuvant intraarterial infusion chemotherapy was performed for 22 hepatectomized patients with Stage III and Stage IV-A hepatocellular carcinoma from July, 1997, to December, 1999.
  • One course of this chemotherapy consisted of cisplatin (10 mg/body/day on days 1-5) followed by 5-FU (250 mg/body/day on days 1-5).
  • One hundred forty-eight patients of Stage III and Stage IV-A underwent hepatectomy from 1992 to 2001 and were enrolled as historical control.
  • There were 9 Stage III cases treated with this adjuvant chemotherapy, and there were 7 or 6 Stage IV-A cases with and without main portal thrombosis, respectively.
  • Survival and disease-free survival curves were not improved compared to historical control by this adjuvant chemotherapy.
  • The number of recurrences in the remnant liver of 2 Stage IV-A cases with main portal thrombosis was limited to 3.
  • Those cases treated with rehepatectomy and transarterial chemoembolization survived about 1,200 days without tumor recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatectomy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619478.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


21. Teratani T, Shiina S, Obi S, Hamamura K, Koike Y, Akamatsu M, Fujishima T, Tateishi R, Imai Y, Shiratori Y, Omata M: [Percutaneous tumor ablation therapy for the advanced stage of HCC]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1496-500
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Percutaneous tumor ablation therapy for the advanced stage of HCC].
  • We have performed percutaneous tumor ablation (PTA) including percutaneous ethanol injection therapy (PEIT) for 90% of the patients with hepatocellular carcinoma.
  • Excluding the patients with Child C whose hepatic function were extremely low, 5 years survival rate reached to the level of 41.2%.
  • Since 5 years survival rate in stage IV-A reached 24.4%, the patients of stage IV-A may be considered to have an indication for PTA.
  • We have confirmed the effectiveness of the local treatment including radiotherapy for advanced hepatocellular carcinoma with portal vein invasion.
  • We are attempting to perform PTA for the extra-hepatic lesions that had no indication of other treatment.
  • However the indication of PTA is limited by the presence of diffuse nodules, exacerbation of the hepatic function, or tumor invasion to portal vein, bile duct, inferior vena cava.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Catheter Ablation. Ethanol / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015992.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


22. Muñoz Martín AJ, Martínez Marín V, Arranz Cózar JL, Cabezón Gutiérrez L, González del Val Subirats R, García Alfonso P: First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab. Clin Transl Oncol; 2008 Mar;10(3):182-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab.
  • There is no standard chemotherapy regimen in advanced gastric cancer with poor performance status and hepatic dysfunction.
  • New chemotherapeutical agents and targeted therapy have demonstrated promising results in terms of efficacy and safety in phase II clinical trials.
  • We report the case of a 68-year-old man with stage IV gastric cancer and severe hepatic dysfunction due to liver metastases treated with a combination of oxaliplatin, 5-fluorouracil and cetuximab.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Diseases / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Cetuximab. Fluorouracil / administration & dosage. Humans. Male. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2256-60 [15150551.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:227-34 [10022258.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1161-7 [12168918.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20 [12422304.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • (PMID = 18321823.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Tanisaka Y, Seike H, Matsumoto T, Tanaka Y, Tsubouchi E, Miyauchi S, Iwakawa K, Ichikawa M: [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1761-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN].
  • He was hospitalized because many venereal diseases had been pointed out in the liver by abdomen ultrasonography.
  • Results of close examination revealed stage IV B with bone metastases, and pulmonary metastases was diagnosed.
  • After consultation, whole-body chemotherapy combining S-1 and PEG-IFN was attempted as of June 26, 2007.
  • S-1 (80 mg/day) was then administered every day for two weeks with drug withdrawal for one week.
  • The liver tumor was markedly reduced, and the pulmonary metastases were also reduced at the completion of 5 courses.
  • The therapeutic effectiveness of this chemotherapy was confirmed by imaging test.
  • The course was favorable, and whole-body chemotherapy was discontinued on January 29, 2008.
  • This treatment method is a promising choice for whole-body chemotherapy for advanced hepatocarcinoma in the future.
  • We have added some review of the literature, and the S-1+PEG-IFN combination chemotherapy is reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Polyethylene Glycols / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Angiography. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Drug Combinations. Hepatitis C, Chronic / complications. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838044.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 30IQX730WE / Polyethylene Glycols; 5VT6420TIG / Oxonic Acid; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


24. Hama N, Kashiwazaki M, Ebisui C, Okubo K, Akitake H, Ohtsuka M, Yamanaka C, Maekawa T, Yoshioka S, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of advanced gastric cancer with liver metastases resected successfully after S-1 monotherapy and S-1/CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2330-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with liver metastases resected successfully after S-1 monotherapy and S-1/CDDP combination chemotherapy].
  • The patient was a 75-year-old man, who was diagnosed with type 3 gastric cancer with solitary liver metastasis whose diameter was 12 mm.
  • Distal gastrectomy with D2 lymph node dissection was performed in June 2008.
  • S-1 monotherapy (120 mg/day, day 1-28/42 days) for liver metastasis started as the first-line chemotherapy.
  • After 3 courses, the diameter of liver metastasis enlarged to 22 mm.
  • Moreover, S-1 and CDDP combined chemotherapy (S-1: 120 mg/day, day 1-21/ 35 days, CDDP: 60 mg/m2, day 8/35 days) was performed as the second-line chemotherapy, nevertheless the diameter of liver metastasis enlarged to 26 mm.
  • No distant metastasis without solitary liver tumor was observed for 6 months after gastric resection, so a partial hepatic resection was performed in February 2009.
  • Five months after the operation, the patient is doing well and shows no signs of recurrence of the cancer.
  • A combination gastrectomy with D2 lymphadenectomy and postoperative chemotherapy was considered to be a radical treatment for H1, Stage IV gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Hepatectomy. Humans. Male

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037412.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Nakamura R, Saikawa Y, Kumagai K, Kiyota T, Ohashi M, Yoshida M, Kubota T, Kumai K, Kitajima M: A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. Int J Clin Oncol; 2007 Aug;12(4):295-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.
  • We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1.
  • The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19.
  • This chemotherapy resulted in significant reduction of the liver and gastric tumors.
  • After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT).
  • With the patient's desire and informed consent, he underwent curative surgery with total gastrectomy, D1+alpha lymph node dissection, and partial resection of liver S4.
  • After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis.
  • At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Male. Middle Aged. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii41-4 [12810457.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(5):391-9 [9771954.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):89-92 [11748462.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:50-7 [12775021.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Oncology. 2001;61(1):16-22 [11474243.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Surgery. 1993 Oct;114(4):799-805; discussion 804-5 [8211697.001]
  • [Cites] Oncol Rep. 2005 May;13(5):865-70 [15809751.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):203-8 [9142380.001]
  • [Cites] Oncology. 1999 Oct;57(3):202-10 [10545788.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):326-9 [12402069.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2328-33 [14556924.001]
  • [Cites] J Gastroenterol. 2000 Dec;35(12):907-11 [11573726.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8 [12109800.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Oncology. 2000 Jun;59(1):14-7 [10895060.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10 (3):687-91 [12684644.001]
  • (PMID = 17701010.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Zhang Z, Fan S: [Liver transplantation for hepatocellular carcinoma: a report of 8 patients]. Zhonghua Wai Ke Za Zhi; 2000 Jun;38(6):415-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation for hepatocellular carcinoma: a report of 8 patients].
  • OBJECTIVE: To evaluate the feasibility of liver transplantation as a treatment for hepatocellular carcinoma (HCC).
  • METHODS: From July 1995 to October 1998, eight liver cancer patients with cirrhosis underwent liver transplantation in Queen Mary Hospital.
  • The liver grafts were obtained from 6 brainstem dead donors and 2 living donors.
  • Five patients had known HCC and 3 had incidental tumor identified in the explanted liver.
  • TNM staging: stage II (5 cases), stage III (2 cases) and stage IV a (1 case).
  • After liver transplantation, the patients were followed up prospectively for a median of 36 months.
  • Except for one patient who had preoperative chemotherapy, no anticancer treatment was given before and after transplantation.
  • RESULTS: Three patients had acute rejection, 5 developed complication in early post transplantation.
  • CONCLUSIONS: Liver transplantation is a feasible method for treatment of HCC in selected patients.
  • Living donor liver transplantation can overcome the problems of donor shortage and tumor growth while waiting for liver transplantation.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832071.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Nakamura H, Kawata S, Takamura M, Osuga K, Murakami T: [Transcatheter arterial embolization for advanced hepatocellular carcinoma--indications and limitations]. Gan To Kagaku Ryoho; 2000 Sep;27(10):1509-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transcatheter arterial embolization for advanced hepatocellular carcinoma--indications and limitations].
  • Many patients with advanced hepatocellular carcinoma (HCC) in stage IV have no surgical indications.
  • Transcatheter methods such as transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy play a main role of the treatment for advanced HCC.
  • Conventional TAE (from proper hepatic artery) is performed for patients without liver dysfunction.
  • Patients with severe liver dysfunction could not in the past be treated with TAE, but lately it has become possible to treat them with the method of segmental TAE or subsegmental TAE due to the development of a microcatheter and advances in equipment.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Iodized Oil / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11015994.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


28. Katayose Y, Unno M: Management of liver metastases from colorectal cancer. Clin J Gastroenterol; 2010 Jun;3(3):128-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of liver metastases from colorectal cancer.
  • About 50% of colorectal cancer patients develop liver metastasis, and liver resection is considered the only curative therapy.
  • Since surgical resection coverage has increased because of improved hepatectomy including portal vein embolization, tumors shrink because of the effectiveness of recent chemotherapy, such as FOLFOX and FOLFIRI, and it has become possible for many patients whose cancer was judged unresectable before to undergo resection.
  • Improvement of new anticancer drugs such as molecularly targeted biologics is greatly changing therapeutic systems of metastatic colorectal cancer, and it is time for us to innovate stage IV therapy.
  • In this report, we will review new treatment strategies for metastatic liver cancer from colorectal cancer, clinical trials of new anticancer drugs for liver metastasis, surgery and ablation as local therapy, and further clarify complex therapeutic systems for metastatic liver tumors from colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] JAMA. 2009 Feb 18;301(7):745-52 [19224751.001]
  • [Cites] Lancet. 1994 Jun 4;343(8910):1405-10 [7515134.001]
  • [Cites] J Clin Oncol. 1985 Jan;3(1):98-102 [3155548.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4298-304 [11731512.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):173-80 [16118771.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3939-45 [16921046.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):771-83 [12866039.001]
  • [Cites] Clin Adv Hematol Oncol. 2010 Jan;8(1):37-9 [20351681.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):38-47 [19942479.001]
  • [Cites] Ann Oncol. 2009 Jul;20(7):1236-41 [19233901.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):1999-2006 [19457654.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1136-40 [9278662.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 [18316791.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Chirurg. 2001 May;72(5):547-60 [11383067.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):661-6 [9718217.001]
  • [Cites] Hepatology. 2001 Aug;34(2):267-72 [11481611.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):626-37 [18936576.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):977-80 [9240140.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Cancer Treat Rev. 2010 Feb;36 Suppl 1:S15-6 [20189055.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):144-57 [17906898.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1670-6 [17470860.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1685-91 [11813601.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] Eur J Surg Oncol. 2009 May;35(5):515-20 [19200687.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):86-96 [15864693.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4 [20189054.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500 [19960344.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):460-6 [14998849.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1830-5 [18398148.001]
  • [Cites] World J Gastroenterol. 2006 Oct 28;12(40):6556-8 [17072991.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] World J Surg. 1986 Oct;10(5):803-8 [3022488.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):256-63 [17458595.001]
  • [Cites] Expert Opin Drug Saf. 2006 Jul;5(4):553-66 [16774493.001]
  • [Cites] J Pathol. 1986 Nov;150(3):195-203 [3806280.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1842-7 [19406901.001]
  • [Cites] World J Surg. 1987 Aug;11(4):511-20 [3630196.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):756-62 [9860474.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2400-3 [14606064.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Br J Cancer. 2009 Oct 6;101(7):1033-8 [19789532.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):97-102 [15864694.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1035-9 [17895897.001]
  • [Cites] Ann Oncol. 2003 Oct;14 (10 ):1537-42 [14504055.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2761-7 [17960603.001]
  • (PMID = 26190118.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Adjuvant / Chemotherapy / Colorectal / Neoadjuvant
  •  go-up   go-down


29. Creţu O, Sima L, Iliescu D, Păscuţ D, Burlacu O, Huţ F, Blidişel A, Târziu R, Fluture V: [Synchronous sigmoid and superior rectal resection and left hepatic lobectomy extended to Spiegel lobe for a sigmoid cancer with hepatic metastasis. Case report]. Rev Med Chir Soc Med Nat Iasi; 2004 Jul-Sep;108(3):635-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous sigmoid and superior rectal resection and left hepatic lobectomy extended to Spiegel lobe for a sigmoid cancer with hepatic metastasis. Case report].
  • [Transliterated title] Rezecţie sincronă, de colon sigmoid şi lobectomie hepatică stângâ extinsă la segmentul I pentru un neoplasm sigmoidian cu metastaze hepatice.
  • The recent developments of surgical technologies allowed the achievement of some standardized interventions with anatomical and functional visa, which based on the improvement of anesthesia and intensive care, and not least by elaboration of efficient chemotherapy protocols, determined new horizons in the treatment of advanced cancers.
  • This work presents a case witch was hospitalized at the Department of Hepatic Surgery, of City Hospital from Timişoara for a colorectal cancer stage IV (T3N1M1), with hepatic metastasis localized at the left hepatic lobe (II and III segments) and Spiegel lobe.
  • A surgical intervention was performed, when in the same operating time was practiced a sigmoid and superior rectal resection (Hartmann) and also a left hepatic lobotomy extended to the first segment.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures / methods. Hepatectomy. Liver Neoplasms / surgery. Rectal Neoplasms / surgery. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832989.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


30. Okabe T, Ohya T, Matsumoto H, Tago K, Totsuka O, Numaga Y, Higuchi T, Iesato H, Yokomori T, Kawate S, Takeyoshi I: [A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine]. Gan To Kagaku Ryoho; 2009 Jan;36(1):115-8
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine].
  • A 68-year-old man underwent total gastrectomy for Type 3 gastric cancer with liver metastasis.
  • The final finding was T3(SE), N1, H1, P0, CY0(class IV), Stage IV, Cur C.
  • After surgery, he was treated with combination chemotherapy of weekly paclitaxel(PTX)/doxifluridine(5'-DFUR).
  • After 2 courses, the tumor marker level normalized, and the size of the liver metastasis was remarkably decreased.
  • After 5 courses, a CT scan revealed the liver metastasis had disappeared, and he has now survived without recurrence after the disappearance of the liver metastasis.
  • This therapy may thus be effective in the treatment of advanced gastric cancer following non-curative operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Humans. Male. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151575.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


31. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • A 66-year-old woman (156 cm, 58 kg) underwent sigmoid colectomy for cancer.
  • She was found to have simultaneous liver and peritoneal metastases at operation, which had not been detected with CT examination before operation.
  • After operation, CT showed multiple liver metastasis and a high level of CEA and CA19-9 .
  • Pathological findings were type 3, 30 x 20 mm, poorly-differentiated adenocarcinoma, se, ly 2, v 2, n 2 (+), ow (-), aw(-), H 3, P 0 (stage IV).
  • Treatment of the patient consisted of daily oral administration of 80 mg TS-1 for 21 days and 60 mg CPT-11 on 1 day and 15 day as one course.
  • After 2 courses, tumor sizes of liver metastases and the level of tumor markers became reduced.
  • The current case suggested that the administration of TS-1 and CPT-11 may have a potent therapeutic efficacy in advanced colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Administration Schedule. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Koyasaki N, Matsumura A, Kamata T, Kanno M: [A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy]. Gan To Kagaku Ryoho; 2002 Apr;29(4):611-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric carcinoma with liver metastasis with no recurrence and long survival by means of surgery and postoperative chemotherapy].
  • A 69-year-old man was diagnosed with type 2 advanced gastric carcinoma at the antrum of the stomach with liver metastasis (S8) in July 1995.
  • Operative staging was H1P0T2N2 stage IV.
  • Distal partial gastrectomy was performed with combined D2 lymphadenectomy and partial hepatectomy.
  • Fifty-six courses of low-dose chemotherapy with CDDP and 5-FU were administered from the time of surgery to March 1997.
  • Aggressive treatment combining surgery and long-term postoperative chemotherapy is potentially useful in contributing to long survival in cases of advanced gastric cancer with liver metastasis.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Gastrectomy. Hepatectomy. Humans. Lymph Node Excision. Male. Survivors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11977549.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


33. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol; 2002 Jun 15;20(12):2789-97
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
  • PURPOSE: To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B).
  • PATIENTS AND METHODS: Forty-six patients were enrolled onto Pediatric Intergroup Hepatoma Protocol INT-0098 (Pediatric Oncology Group (POG) 8945/Children's Cancer Group (CCG) 8881).
  • After initial surgery or biopsy, children with stage I (n = 8), stage III (n = 25), and stage IV (n = 13) HCC were randomly assigned to receive regimen A (n = 20) or regimen B (n = 26).
  • Patients with stage I, III, and IV had 5-year EFS estimates of 88% (SD = 12%), 8% (SD = 5%), and 0%, respectively.
  • Events occurred before postinduction surgery I in 18 (47%) of 38 patients with stage III or IV disease, and tumor resection was possible in two (10%) of the remaining 20 children with advanced-stage disease after chemotherapy.
  • CONCLUSION: Children with initially resectable HCC have a good prognosis and may benefit from the use of adjuvant chemotherapy.
  • Outcome was uniformly poor for children with advanced-stage disease treated with either regimen.
  • New therapeutic strategies are needed for the treatment of advanced-stage pediatric HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Male. Neoplasm Staging. Prognosis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065555.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA092049
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Takeyama H, Sawai H, Wakasugi T, Takahashi H, Matsuo Y, Ochi N, Yasuda A, Sato M, Okada Y, Funahashi H, Akamo Y, Manabe T: Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases. World J Surg Oncol; 2007;5:79
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful paclitaxel-based chemotherapy for an alpha-fetoprotein-producing gastric cancer patient with multiple liver metastases.
  • BACKGROUND: Alpha-fetoprotein (AFP)-producing gastric cancer is known to frequently cause multiple liver metastases and to have an extremely poor prognosis.
  • CASE PRESENTATION: A 64-year-old Japanese man admitted to our hospital was diagnosed with gastric cancer with liver metastases.
  • He underwent a total gastrectomy with splenectomy, and pathological stage IV disease according to the classification proposed by the Japanese Gastric Cancer Association was assigned.
  • The histological diagnosis was poorly differentiated adenocarcinoma, and tumor production of AFP was confirmed by immunohistochemical staining.
  • Following surgery, the patient received combination chemotherapy consisting of TS-1 and paclitaxel.
  • Initially, AFP levels decreased dramatically and computed tomography (CT) revealed regression of liver metastases.
  • However, multiple new liver metastases appeared and serum AFP levels increased after 5 months.
  • Serum AFP levels once again decreased and CT showed regression or disappearance of liver metastases.
  • No progression of liver metastases has been observed to date.
  • CONCLUSION: We consider this rare case to have significant value with respect to treatment of AFP-producing gastric cancer with multiple liver metastases, and propose that combining surgery with chemotherapeutic agents such as paclitaxel may lead to a better prognosis in such cases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Liver Neoplasms / secondary. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2003;38(6):540-7 [12825129.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2965-8 [16080552.001]
  • [Cites] Oncology. 2000 Aug;59(2):145-51 [10971174.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1133-7 [11583196.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Surg Today. 2002;32(5):429-33 [12061695.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Surg Today. 2002;32(12):1075-80 [12541026.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Apr;33(4):517-9 [16612165.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):809-13 [15010877.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Presse Med. 1970 Jun 6;78(28):1277-8 [5426134.001]
  • [Cites] N Engl J Med. 1971 Nov 4;285(19):1058-9 [4106197.001]
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):654-61 [7508672.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Aug;21(10):1659-63 [7520221.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 6:S3-6 [7865431.001]
  • [Cites] Gen Diagn Pathol. 1995 May;141(1):61-5 [8542509.001]
  • [Cites] Gan To Kagaku Ryoho. 1996 Aug;23(9):1197-200 [8751810.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):203-8 [9142380.001]
  • [Cites] Pathologica. 1997 Jun;89(3):310-6 [9380425.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1658-63 [10364040.001]
  • [Cites] Scand J Clin Lab Invest. 1956;8(2):174 [13351554.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 May;27(5):735-8 [10832443.001]
  • (PMID = 17634124.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1939849
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


35. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer; 2003 Apr 15;97(8):2006-12
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrolamellar hepatocellular carcinoma in children and adolescents.
  • BACKGROUND: Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC.
  • METHODS: Forty-six patients were enrolled on Pediatric Intergroup Hepatoma Protocol INT-0098 (Pediatric Oncology Group Study 8945/Children's Cancer Group Study 8881) between August 1989 and December 1992.
  • After undergoing initial surgery or biopsy, children with Stage I HCC (n = 8 patients), Stage III HCC (n = 25 patients), and Stage IV HCC (n = 13 patients) were assigned randomly, regardless of histology, to receive treatment either with cisplatin, vincristine, and fluorouracil (n = 20 patients) or with cisplatin and continuous-infusion doxorubicin (n = 26 patients).
  • There was no difference in the number of patients with advanced-stage disease, the incidence of surgical resectability at diagnosis, or the response to treatment between patients with FL-HCC and patients with typical HCC.
  • CONCLUSIONS: Children with FL-HCC do not have a favorable prognosis and do not respond any differently to current therapeutic regimens than patients with typical HCC.
  • Children with initially resectable HCC have a good prognosis irrespective of histologic subtype, whereas outcomes are poor uniformly for children with advanced-stage disease.
  • The use of novel chemotherapeutic agents and the incorporation of other treatment modalities are indicated to improve the dismal survival of pediatric patients with all histologic variants of advanced-stage HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cisplatin / administration & dosage. Cohort Studies. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Hepatoblastoma. Humans. Infant. Infusions, Intravenous. Male. Neoplasm Staging. Prognosis. Prospective Studies. Risk Factors. Time Factors. Treatment Outcome. Vincristine / administration & dosage. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12673731.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 36
  •  go-up   go-down


36. Ohchi T, Kikuchi N, Doi K, Ogata K, Ishimoto T, Furuhashi S, Ogawa M, Ishihara A: [A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy]. Gan To Kagaku Ryoho; 2006 Feb;33(2):231-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 6-year-survival case of esophageal adenosquamous cancer with liver metastases cured by multidisciplinary therapy].
  • A 65-year-old man was diagnosed as esophageal cancer with multiple liver metastases (S2 10 mm, S7 10 mm, S8 15 mm).
  • The preoperative diagnosis was stage IV (T 3 N 3 M 1 Pl 0), and he was operated palliatively by esophagocardiofundectomy and intrathoracic anastomosis for oral food intake.
  • The postoperative histological diagnosis was adenosquamous carcinoma.
  • He was also treated by hepatic arterial infusion therapy with CDDP (10 mg/week).
  • After 180 mg of CDDP, liver metastases were evaluated for PR.
  • This therapy was discontinued after 410 mg of CDDP by vomiting and hypotension.
  • 16 months after, DOC (20 mg/week) was given by arterial infusion and CR of liver metastases was achieved 18 months after.
  • He was free from the recurrence of cancer as an outpatient and had a good QOL.
  • We think that esophageal cancer with liver metastasis should be aggressively treated surgically so as to allow oral food intake, and liver metastasis should be treated with chemotherapy because postoperative hepatic arterial infusion therapy is effective and provides a good QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Anastomosis, Surgical / methods. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Esophagus / surgery. Gastric Fundus / surgery. Humans. Male. Proteoglycans / administration & dosage. Quality of Life. Survivors. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484862.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proteoglycans; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 66455-27-4 / krestin; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


37. Egberts F, Kahler KC, Livingstone E, Hauschild A: Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie; 2008 Jul;31(7):398-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
  • In advanced metastatic melanoma (AJCC stage IV), the prognosis is still poor, and views differ on the appropriate systemic treatment for these patients.
  • Therefore, new approaches in therapeutic regimens are mandatory.
  • Sorafenib is an oral multikinase inhibitor that targets 2 classes of kinases which are known to be involved in both tumor proliferation and angiogenesis.
  • Sorafenib has been evaluated as a single therapy agent as well as in combination with various chemotherapeutical drugs in a number of clinical trials.
  • The vast majority of clinical data exists for patients with advanced renal cell cancer for which sorafenib has been approved by the FDA and EMEA.
  • Very recently, sorafenib was approved for advanced hepatocellular cancers due to its overall survival improvement.
  • However, as a single-agent therapy, sorafenib seems to be of limited use.
  • [MeSH-major] Benzenesulfonates / administration & dosage. Clinical Trials as Topic / trends. Evidence-Based Medicine. Melanoma / drug therapy. Melanoma / secondary. Pyridines / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Humans. Niacinamide / analogs & derivatives. Phenylurea Compounds. Science / trends. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18596389.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Number-of-references] 19
  •  go-up   go-down


38. Park KW, Park JW, Cho SH, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Kim DY, Hong EK, Kim CM: [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. Korean J Hepatol; 2006 Mar;12(1):41-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities].
  • BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is 3rd leading cause of cancer in Korea and the prognosis for HCC patients is poor.
  • For assessing the present treatment outcome, this study analyzed the three-year survival rate (3-YSR) and the prognostic factors for patients with HCC in Korea.
  • METHODS: Between November 2000 and December 2003, 905 patients with HCC who were diagnosed and treated at the National Cancer Center Korea were enrolled in this study.
  • The clinical variables, tumor characteristics and survival periods were analyzed.
  • The overall 3-YSR of the patients with modified UICC stage I, II, III, IVa and IVb were 67.4%, 65.2%, 30.7%, 9.0% and 5.0%, respectively.
  • The modified UICC stage could not differentiate stage I from II, and stage IVa from IVb, on the 3-YSR.
  • The 3-YSR of the Child-Pugh class A patients with modified UICC stage I or II was 85.4% by surgical resection and it was 69.6% by transcatheter chemoembolization (TACE), respectively (P= .461), and those values for patients with stage III were 49.2% and 36.8%, respectively (P=.081).
  • As compared with systemic chemotherapy or conservative therapy, TACE increased the survival rate more for the Child-Pugh class A patients with stage IV.
  • The independent prognostic factors were serum AFP, portal vein thrombosis, the Child-Pugh classification and the stage of HCC.
  • CONCLUSIONS: This follow-up study will be helpful in assessing the results of treatments for HCC and it will provide data for the establishment of a more effective treatment strategy.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565605.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


39. Sasaki F, Matsunaga T, Iwafuchi M, Hayashi Y, Ohkawa H, Ohira M, Okamatsu T, Sugito T, Tsuchida Y, Toyosaka A, Nagahara N, Nishihira H, Hata Y, Uchino J, Misugi K, Ohnuma N, (Japanese Study Group for Pediatric Liver Tumor): Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg; 2002 Jun;37(6):851-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor.
  • PURPOSE: Hepatoblastoma is the most common malignant liver tumor in childhood.
  • This report reviews the results of the Japanese Study Group for Pediatric Liver Tumor Protocol-1 (JPLT-1) and compares its outcomes with published reports of other studies.
  • METHODS: From March 1991 to December 1999, 154 patients with malignant liver tumor including 145 cases of hepatoblastomas were enrolled in the JPLT study.
  • JPLT-1 protocol 91A was used for patients with stage I or II hepatoblastoma.
  • The chemotherapy regimen consisted of repeated courses of cisplatin (CDDP), 40 mg/m(2), and tetrahydropyranyl (THP)-Adriamycin, 30 mg/m(2).
  • JPLT-1 protocol 91B was administered to patients with stage IIIA, IIIB, or IV hepatoblastoma.
  • The chemotherapy regimen consisted of repeated courses of CDDP, 80 mg/m(2), and THP-Adriamycin, 30 mg/m(2)/day for 2 days.
  • RESULTS: Seven patients died of chemotherapy-related side effects.
  • Six of them died of sepsis caused by leukopenia and 1 case of liver failure.
  • Overall survival rate (3-year/6-year) was 100%/100% for stage I (n = 9), 100%/95.7% for stage II (n = 32), 76.6%/73.8% for stage IIIA (n = 48), 50.3%/50.3% for stage IIIB (n = 25), 64.8%/38.9% for stage IV (n = 20), and 77.8%/73.4% overall.
  • For stage IIIA and B disease, intravenous chemotherapy was better than intraarterial chemotherapy (66.4% v 38.1% for event-free survival and 69.3% v. 57.1% for overall survival).
  • Patients less than 1 year of age had a better prognosis than older patients, but age was not a significant prognostic factor by multivariate analysis.
  • The event-free survival rate at 3 years for stage IIIB and IV disease was under 50%.
  • New treatment strategies are needed for patients with advanced hepatoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Female. Humans. Infant. Infant, Newborn. Injections, Intra-Arterial. Injections, Intravenous. Male. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12037748.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW: Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol; 2010 Dec;17(12):3104-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma.
  • BACKGROUND: Lack of health insurance is associated with poorer outcomes for patients with cancers amenable to early detection.
  • The effect of insurance status on hepatocellular carcinoma (HCC) presentation stage and treatment outcomes has not been examined.
  • We examined the effect of health insurance status on stage of presentation, treatment strategies, and survival in patients with HCC.
  • METHODS: The Tennessee Cancer Registry was queried for patients treated for HCC between January 2004 and December 2006.
  • (2) government insurance (non-Medicaid);.
  • Logistic, Kaplan-Meier, and Cox models tested the effects of demographic and clinical covariates on the likelihood of having surgical or chemotherapeutic treatments and survival.
  • The uninsured were more likely to present with stage IV disease (P = 0.005).
  • After adjusting for demographics and tumor stage, Medicaid and uninsured patients were less likely to receive surgical treatment (both P < 0.01) but were just as likely to be treated with chemotherapy (P ≥ 0.243).
  • Survival was significantly better in privately insured patients and in those treated with surgery or chemotherapy (all P < 0.01).
  • CONCLUSIONS: Uninsured patients with HCC are more likely to present with late-stage disease.
  • Although insurance status did not affect chemotherapy utilization, Medicaid and uninsured patients were less likely to receive surgical treatment.
  • [MeSH-major] Antineoplastic Agents / economics. Carcinoma, Hepatocellular / economics. Catheter Ablation / economics. Hepatectomy / economics. Insurance, Health. Liver Neoplasms / economics. Liver Transplantation / economics
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Insurance Coverage. Male. Middle Aged. Neoplasm Staging. Registries. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Health Insurance.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585872.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / T32 HS 013833
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


41. Lin AY, Fisher GA, So S, Tang C, Levitt L: Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol; 2008 Feb;31(1):84-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib in unresectable hepatocellular carcinoma.
  • BACKGROUND: The expression of platelet-derived growth factor, a potent mitogen, and its receptor both in tissue and serum correlate with the severity of liver cirrhosis.
  • Over-expression of platelet-derived growth factor has been demonstrated in human hepatocellular carcinoma (HCC) tumors and cell lines.
  • METHODS: Eligibility criteria consisted of HCC patient over the age of 18 with reasonable organ function, unresectable but measurable disease, not candidates for chemoinfusion, and a performance status of 0 to 2.
  • Metastatic disease (American Joint Committee on Cancer stage IV) was noted in 13 patients and locally advanced (stage III) in the remainder.
  • The median dose-level of imatinib was 500 mg/d.
  • No grade 3 or 4 hematologic toxicity was observed.
  • Two patients had grade 3 elevated liver function tests during treatment; otherwise, there was no other grade 3 or 4 nonhematologic toxicity noted.
  • CONCLUSION: Although toxicities were tolerable, imatinib as a monotherapy for the treatment of unresectable HCC has little, if any, significant efficacy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Female. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Humans. Imatinib Mesylate. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376233.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


42. Chia WK, Ong S, Toh HC, Hee SW, Choo SP, Poon DY, Tay MH, Tan CK, Koo WH, Foo KF: Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore; 2008 Jul;37(7):554-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.
  • INTRODUCTION: Advanced hepatocellular carcinoma (HCC) has a dismal prognosis and is notoriously chemo-resistant.
  • We conducted a Phase II prospective study to evaluate the activity and tolerability of gemcitabine and cisplatin in chemo-naïve advanced hepatocellular carcinoma.
  • Utilising a Simon's minimax two-stage design with a type I error of 0.05 and power of 80%, 25 subjects would be required.
  • Fifteen patients would be needed in stage 1 and if fewer than 2 responses were observed, the trial would be stopped and lack of efficacy claimed.
  • Assessment of response based on computer tomography was performed after every 2 cycles of chemotherapy.
  • Two patients had Child C liver cirrhosis, 5 patients had Child B cirrhosis, and the remaining 8 patients had Child A cirrhosis.
  • This regime was well tolerated and there was only 1 patient who experienced grade IV toxicities.
  • A further 3 patients experienced stable disease and 11 patients progressed on chemotherapy.
  • The median time to progression was 6 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695766.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Pham TH, Iqbal CW, Grams JM, Zarroug AE, Wall JC, Ishitani MB, Nagorney DM, Moir C: Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg; 2007 May;42(5):834-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of primary liver cancer in children: an appraisal of experience.
  • INTRODUCTION: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the most common primary liver cancers in children.
  • Recent advances in management of pediatric liver cancer have improved disease-specific survival (DSS).
  • This is a review of our experience with childhood liver malignancy over the past 3 decades.
  • MATERIALS AND METHODS: A retrospective chart review from 1975 to 2005 identified patients who were 18 years old or younger with a histologically confirmed diagnosis of primary liver cancer.
  • Patients were staged according to the Children's Cancer Group and Pediatric Oncology Group (CCG/POG) system.
  • RESULTS: Fifty-two patients were confirmed to have primary liver cancers, where 24 (46%) patients had HB, 22 (42%) had HCC, 3 (6%) had sarcomas, and 3 (6%) had other histologies.
  • Most patients underwent major liver resection (n = 45, 87%), including: lobectomy (n = 25, 48%), and trisegmentectomy (n = 11, 21%).
  • Three patients underwent liver transplantation (n = 3, 6%) for advanced local disease.
  • Forty-five (87%) received primary or neoadjuvant and/or adjuvant chemotherapy.
  • Patients had the following CCG/POG stages: I (n = 31, 60%), II (n = 6, 11.5%), III (n = 9, 17%), and IV (n = 6, 11.5%).
  • Complete gross resection (stage I and II) was achieved in 37 (71%) patients.
  • CONCLUSION: Complete resection of the pediatric primary liver tumors remains the cornerstone of treatment to achieve cure.
  • Major liver resection can be performed with minimal perioperative mortality and morbidity.
  • Liver transplantation in conjunction with chemotherapy may have an increasing role in the management of locally advanced primary liver cancers.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Hepatoblastoma / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Child. Child, Preschool. Combined Modality Therapy. Hepatectomy. Humans. Liver Transplantation. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502194.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Patiutko IuI, Chuchuev ES, Kotel'nikov AG, Sagaĭdak IV, Badalian KhV: [Synchronous operations in metastatic cancer of the liver]. Khirurgiia (Mosk); 2006;(5):14-7
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous operations in metastatic cancer of the liver].
  • The resection of the liver has been performed in 661 patients including 154 (23.3%) cases of synchronous metastatic cancer of the liver.
  • Among the latter patients primary tumor was removed in one stage with liver resection in 56% cases.
  • Elderly age of the patients, multiple bilobular foci in the liver, size of the foci more than 10 cm, traumatic operations on the primary focus were not contraindications to synchronous operations.
  • Surgical treatment for colorectal cancer should be supplemented with adjuvant chemotherapy.
  • The long-term results demonstrate better survival after synchronous operations for colorectal cancer.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Aged. Female. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858334.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


45. Rizzetto M: Hepatocellular carcinoma: screening and therapy. Minerva Gastroenterol Dietol; 2000 Sep;46(3):143-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: screening and therapy.
  • Treatment of the liver cancer (LC) patient is often problematic as the tumour is identified at an advanced stage: the frequent coexistence of cirrhosis limits the use of surgical resection, there is no efficacious chemotherapy, and in patients treatable with liver transplant, indication is rendered uncertain from the point of view of cost-effectiveness and the high risk of recurrence of the tumour and hepatitis infection.
  • Surgical resection appears to be the treatment of choice in patients with a liver tumour in a ''healthy'' liver.
  • Instead, orthotopic liver transplant is the most valid indication for patients with cirrhosis and tumours of dimensions smaller than 2-3 cm.
  • Nevertheless, due to the lack of organs palliative treatments, like surgical resection, PEI and TACE are the most indicated in patients with advanced neoplastic disease, in practice patients with TNM III and IV; radiotherapy with protons and the coagulation of the tumour by microwaves or laser fibres are also used in the attempt to slow down the progress of the neoplastic process.
  • In some patients the most effective approach may be the combined use of various therapies, such as TACE, PEI and surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498375.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Gervain J: [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening]. Orv Hetil; 2010 Aug 29;151(35):1415-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening].
  • Early stage hepatocellular carcinoma is a symptom-free disease.
  • Local and general symptoms occur due to the growth of the tumor tissue and the infiltration of the surrounding blood vessels.
  • Illness progression is indicated by the development of abdominal discomfort, cachexia, therapy-resistant decompensation of previously compensated cirrhosis and in severe cases, the thrombosis of the portal vein or the hepatic veins.
  • Characteristic laboratory findings are the quickly deteriorating blood and liver function tests results, the occurrence of haemostatic disorders and occasional hypoglycemia and/or hypercalcemia.
  • To clarify the etiology and to identify high risk patients, we need to differentiate alcohol-, drug- or chemical-induced hepatic disorders, viral hepatitis B, C and Delta, metabolic disorders and non-alcoholic steatohepatitis.
  • In the case of focal hepatic lesions, persistently elevated alfa fetoprotein levels have a high diagnostic value.
  • At levels over 200 ng/ml, the positive predictive value is >90%.
  • Other, less commonly measured biomarkers are the glycosilated alfa fetoprotein-L3 and the vitamin K-deficiency induced des-gamma-carboxy prothrombin.
  • The risk of tumor occurrence is multiple in patients with HbeAg positive chronic hepatitis B if the virus is of genotype C with mutations in the 1762 and 1764 locations of the core promoter region.
  • Abdominal ultrasound and measurement of alfa fetoprotein is recommended every 6 months for high risk individuals, or every 3-4 months over an 18-24 months period for patients with hepatic lesions of <1cm and of unknown malignancy.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / prevention & control. Liver Neoplasms / diagnosis. Liver Neoplasms / prevention & control. Mass Screening / methods
  • [MeSH-minor] Alcohol Drinking / adverse effects. Biomarkers / blood. Drug-Induced Liver Injury / complications. Early Detection of Cancer. Fatty Liver / complications. Hepatitis, Viral, Human / complications. Humans. Protein Precursors / blood. Prothrombin. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719715.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


47. Xiong ZP, Zhang YD, Huang F, Liang ZY: [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Aug;29(8):623-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the efficiency and safety of transhepatic arterial chemoembolization (TACE) with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma (HCC).
  • The toxicity and hepatic damage were observed according to WHO anticancer drug toxicity criteria and Child-Pugh classification criteria, respectively.
  • The survival time was also observed during follow-up.
  • RESULTS: The blood toxicity was bone marrow suppression presented as grade I leucopenia in 39.3%, grade II in 29.5%, grade III-IV in 18.0%.
  • Grade II-III nausea and vomiting developed in 96.8% of the patients.
  • Hepatic function damage became aggravated in 16 patients from A to B class, in 2 from A to C class, and in 6 from B to C class according to Child-Pugh classification criteria.
  • The median survival time was 20 months with a range of 5 to 3 5 months.
  • CONCLUSION: Transhepatic arterial chemoembolization using carboplatin and mixture of gemcitabine with ultra-lipoidal iodide oil emulsion is safe and effective in the management of stage III hepatocellular carcinoma.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Deoxycytidine / analogs & derivatives. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210886.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


48. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M: Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract; 2010 Jul;64(8):1034-41
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is a complicated condition influenced by multiple confounding factors, making optimum patient management extremely challenging.
  • Ethnicity, stage at diagnosis, comorbidities and tumour morphology affect outcomes and vary from region to region, and there is no common language to assess patient prognosis and make treatment recommendations.
  • Non-surgical treatments include ablation, transarterial chemoembolisation and the multikinase inhibitor, sorafenib, but their effects in all patient subgroups are not known and further information is needed to optimise the use of these treatments.
  • AIMS: The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) study (ClinicalTrials.gov identifier NCT00812175; http://clinicaltrials.gov/) is an ongoing global, prospective, non-interventional study of patients with unresectable HCC who are eligible for systemic therapy and for whom the decision has been taken to treat with sorafenib under real-life practice conditions.
  • DISCUSSION: This study will recruit 3000 patients from > 40 countries and follow them for approximately 5 years to compile a large and robust database of information that will be used to analyse local, regional and global differences in baseline characteristics, disease aetiology, treatment practice patterns and treatment outcomes, with a view to improve the knowledge base used to guide physician treatment decisions and to improve patient outcomes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Clinical Trials as Topic / methods. Liver Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Clinical Trials, Phase IV as Topic / methods. Humans. Niacinamide / analogs & derivatives. Patient Selection. Phenylurea Compounds. Prospective Studies. Research Design. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jun 1;23(11):1535-47 [16696801.001]
  • [Cites] Keio J Med. 2009 Sep;58(3):161-75 [19826210.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55 [19759364.001]
  • [Cites] Korean J Radiol. 2009 Sep-Oct;10(5):425-34 [19721826.001]
  • [Cites] Lancet Oncol. 2009 Jan;10(1):25-34 [19095497.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] Clin Ther. 2007 Jun;29(6 Pt 1):1284-92 [18036390.001]
  • [Cites] Ann Intern Med. 2007 Oct 16;147(8):W163-94 [17938389.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4293-300 [16908937.001]
  • (PMID = 20642705.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00812175
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2905618
  •  go-up   go-down


49. Castaldo ET, Pinson CW: Liver transplantation for non-hepatocellular carcinoma malignancy. HPB (Oxford); 2007;9(2):98-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for non-hepatocellular carcinoma malignancy.
  • Liver transplantation (LT) for hepatocellular carcinoma is effective for selected patients.
  • LT for other malignancies like cholangiocarcinoma (CCA), hepatoblastoma (HB), hepatic epithelioid hemangioepithelioma (HEHE), angiosarcoma (AS), and neuroendocrine tumors (NET) is being defined.
  • For CCA, series that did not emphasize highly selected early stage disease and neoadjuvant or adjuvant chemoradiation had an average 5-year survival of 10%.
  • However, emphasizing neoadjuvant radiation and chemosensitization in operatively confirmed stage I or II hilar CCA has led to improved 5-year survival, up to 82%.
  • LT is indicated under strict research protocols at selected centers, for patients with early stage CCA and anatomically unresectable (Bismuth type IV) lesions.
  • HB is typically sensitive to cisplatin-based chemotherapy.
  • LT plays a role as primary surgical therapy for those individuals in whom tumors remain unresectable after chemotherapy or as rescue therapy for those who are incompletely resected, recur after resection, or develop hepatic insufficiency after chemotherapy and/or resection.
  • HEHE is a multifocal tumor that lies somewhere between benign hemangiomas and malignant AS.
  • However, AS is an aggressive tumor and LT is contraindicated.
  • For NET, resection of the primary tumor and all gross metastatic disease is reported to provide 5-year survival of 70-85%.
  • LT has been employed for some patients for unresectable tumors or for palliation of medically uncontrollable symptoms with 5-year survival reported between 36% and 80%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • [Cites] Ann Surg. 1988 Apr;207(4):373-9 [2451484.001]
  • [Cites] Ann Surg. 1989 Jan;209(1):88-98 [2535924.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):483-7 [8591077.001]
  • [Cites] Hepatology. 1996 May;23(5):1105-11 [8621141.001]
  • [Cites] Ann Surg. 1997 Apr;225(4):347-54 [9114792.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):62-70 [9627173.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):358-64 [9783781.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] Liver Transpl. 2000 May;6(3):317-9 [10827232.001]
  • [Cites] Transplantation. 2000 Apr 27;69(8):1633-7 [10836374.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):795-804 [10839879.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S23-9 [11084081.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] J Pediatr Surg. 2002 Feb;37(2):240-5 [11819207.001]
  • [Cites] Transplantation. 2002 Feb 15;73(3):386-94 [11884935.001]
  • [Cites] World J Surg. 2002 Aug;26(8):998-1004 [12016481.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Am J Transplant. 2002 Jul;2(6):535-8 [12118897.001]
  • [Cites] Am J Transplant. 2002 Sep;2(8):774-9 [12243499.001]
  • [Cites] Transplantation. 2002 Sep 15;74(5):652-5 [12352881.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):210-9 [14745329.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):265-71 [14745336.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):74-83 [14752798.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):208-12 [15036197.001]
  • [Cites] J Pediatr. 2005 Feb;146(2):204-11 [15689909.001]
  • [Cites] Transplant Proc. 2005 Jun;37(5):2195-9 [15964377.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):283-4 [16041278.001]
  • [Cites] J R Soc Med. 2005 Aug;98(8):364-5 [16055903.001]
  • [Cites] Am J Transplant. 2005 Sep;5(9):2229-35 [16095502.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Semin Pediatr Surg. 2005 Nov;14(4):233-8 [16226698.001]
  • [Cites] Liver Transpl. 2005 Nov;11(11):1412-6 [16237695.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S109-12 [16286886.001]
  • [Cites] J Pediatr Surg. 2006 Jan;41(1):182-6 [16410130.001]
  • [Cites] Surgery. 1990 Dec;108(6):1091-6 [1701060.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1502-22 [2443618.001]
  • [Cites] Liver Transpl. 2000 May;6(3):309-16 [10827231.001]
  • (PMID = 18333123.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020792
  •  go-up   go-down


50. Bhagat V, Javle M, Yu J, Agrawal A, Gibbs JF, Kuvshinoff B, Nava E, Iyer R: Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer; 2006;37(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Combined hepatocholangiocarcinoma (CHCC) is an infrequent primary hepatic malignancy with no clearly defined diagnostic criteria, poorly studied natural history, and no guidelines regarding therapy.
  • Eight cases were identified; histological and immunohistochemical criteria used for diagnosis were defined.
  • Abdominal pain (n = 6), hepatomegaly (n = 4), and elevated CA 19-9 >40 U/mL (n = 4/5) were frequent.
  • Early TNM stage (I and II) compared with advanced disease (III and IV) correlated with higher overall survival on univariate analyses [37 and 6 mo respectively (p = 0.011)].
  • Median overall survival was significantly higher in patients who underwent potentially curative resection (23 mo, range 4-48+) compared with patients who underwent non-surgical therapies such as transcatheter arterial chemoembolization and chemotherapy (2 mo, range 1-8) (p = 0.0357, one-sided exact log-rank test).
  • Surgical resection and early stage at diagnosis predict longer survival.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Cholangiocarcinoma / complications. Liver Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. CA-19-9 Antigen / blood. Cholelithiasis / epidemiology. Female. Hepatitis B, Chronic / epidemiology. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1996 Oct;149(4):1167-75 [8863666.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):292-8 [15288479.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Surg Clin North Am. 1999 Feb;79(1):43-57, viii [10073181.001]
  • [Cites] Liver. 1995 Feb;15(1):9-15 [7539881.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):643-57 [15062666.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):742-8 [9630182.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Histopathology. 1989 May;14(5):503-13 [2472345.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2000 Jul;491:1-412 [12563349.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1157-62 [15788587.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):56-60 [14745254.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Feb 25;52(2):155-63 [1313961.001]
  • [Cites] Liver. 2002 Feb;22(1):43-50 [11906618.001]
  • [Cites] Jpn J Cancer Res. 1996 Oct;87(10):1056-62 [8957064.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):35-41 [11748452.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):965-6 [10580599.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1978 Jun;9(2):215-9 [214874.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;31 Suppl:S38-44 [1333907.001]
  • [Cites] Natl Toxicol Program Tech Rep Ser. 2002 May;(504):1-357 [12087420.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] J Agric Food Chem. 2000 Aug;48(8):3620-32 [10956160.001]
  • [Cites] Am J Surg. 2005 Jan;189(1):120-5 [15701504.001]
  • [Cites] Chir Ital. 1999 Jan-Feb;51(1):1-7 [10514910.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):738-43 [11710692.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 1992 Jun;30(6):342-5, 382 [1337514.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):298-304 [14739102.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • [Cites] Gan To Kagaku Ryoho. 1993 Feb;20(2):295-8 [8382037.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):191-211, v [15831268.001]
  • (PMID = 17290078.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  • [Number-of-references] 37
  •  go-up   go-down


51. Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L: A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs; 2008 Jun;26(3):265-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
  • Hepatocellular carcinoma (HCC) remains a lethal treatment-resistant cancer with a median survival of <6 months in patients not considered candidates for radical surgical treatments.
  • A non-randomized, non-blinded multicentre two-stage phase II study was completed examining the efficacy, toxicity, and pharmacokinetics of SB-715992 at 18 mg/m2 IV q 3 weeks, in patients with measurable locally advanced, metastatic or recurrent HCC.
  • The predictive value of KSP in archival tumour was assessed.
  • The most common grade 3+ toxicities were granulocytopenia, leukocytopenia, diarrhea and liver transaminase rise.
  • Seven (46%) patients had a best response of stable disease at the 8-week evaluation (median duration 3.9 months) Median time to progression was 1.61 months (95%CI = 1.31-3.94 months) SB-715992 plasma concentrations were comparable to those observed in the phase I studies.
  • Among these patients with preserved hepatic function and good performance status, SB-715992 was generally well tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression. Humans. Infusions, Intravenous. Kinesin / antagonists & inhibitors. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):127-34 [12735134.001]
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Hepatology. 2000 Sep;32(3):679-80 [10991637.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):370-7 [11710735.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):531-40 [1356418.001]
  • [Cites] Science. 2000 Apr 7;288(5463):88-95 [10753125.001]
  • [Cites] Semin Liver Dis. 1999;19(3):311-22 [10518310.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):97-105 [10077227.001]
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2175-85 [14640916.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):479-83 [2839280.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1094-101 [10694562.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • (PMID = 18196204.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / KIF11 protein, human; 0 / Quinazolines; BKT5F9C2NI / ispinesib; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


52. Das UN: Occlusion of infusion vessels on gamma-linolenic acid infusion. Prostaglandins Leukot Essent Fatty Acids; 2004 Jan;70(1):23-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the effect of lithium salt of GLA conjugated to iodized lymphographic oil (LGIOC) was injected intra-arterially close to the origin of tumor-feeding vessel(s) was studied.
  • Four patients with stage 4 cancer disease (2 with hepatocellular carcinoma, 1 with giant cell tumor of the bone, and one with renal cell carcinoma), were selected for the study.
  • Angiography, radiography and computed axial tomography were performed prior to and immediately after the injection of LGIOC and at periodic intervals.
  • All four patients tolerated the treatment well.
  • The most significant observation was the complete occlusion of the tumor-feeding vessels after LGIOC injection.
  • Follow-up angiograms performed in all the patients showed occlusion of the tumor-feeding vessels is more or less permanent.
  • A significant reduction in the size of the tumor was also observed in these patients.
  • LGIOC showed occlusion of tumor-feeding vessels after infusion, and further studies are needed to confirm these preliminary results.
  • [MeSH-major] Neoplasms / drug therapy. gamma-Linolenic Acid / administration & dosage. gamma-Linolenic Acid / pharmacology
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Giant Cell Tumor of Bone / drug therapy. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14643176.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 78YC2MAX4O / gamma-Linolenic Acid
  •  go-up   go-down


53. Ochiai T, Sonoyama T, Ikoma H, Kuriu Y, Nakanishi M, Kubota T, Kikuchi S, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Kokuba Y, Otsuji E: Salvage surgery for uncontrollable hepatocellular carcinoma treated with repeated non-surgical therapies. Hepatogastroenterology; 2010 Jul-Aug;57(101):858-64
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery for uncontrollable hepatocellular carcinoma treated with repeated non-surgical therapies.
  • BACKGROUND/AIMS: Some hepatocellular carcinoma (HCC) cases undergo surgery because tumor progression cannot be controlled by various non-surgical therapies.
  • METHODOLOGY: Among cases with solitary small HCCs (< or = 3.0cm at the time of detection), the clinicopathologic features of 7 patients who had undergone hepatectomy after various non-surgical therapies (Salvage (S) group) were analyzed and compared with those of 30 patients who received hepatectomy as the initial treatment (Control (C) group).
  • RESULTS: In S group, the serum alpha-fetoprotein level was higher (p = 0.045) and macroscopic ductal invasion was more common (p = 0.028) at the time of the operation.
  • Lobectomy was more commonly performed (p = 0.034) and curability B (No residual cancer, but Stage III or IV) was more frequent (p = 0.011).
  • The survival time after the initial treatment (post-initial treatment survival) was worse (p = 0.028).
  • Univariate analyses revealed that those with maximum tumor sizes of > 3.0 cm at the time of the operation were significantly worse compared with the other patients (p = 0.012).
  • CONCLUSIONS: The timing for changing from a non-surgical treatment to a surgical treatment is important.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Salvage Therapy
  • [MeSH-minor] Aged. Catheter Ablation. Chemoembolization, Therapeutic. Disease Progression. Female. Hepatic Duct, Common / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033242.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement